Randall E. Millikan

7.1k total citations
87 papers, 5.2k citations indexed

About

Randall E. Millikan is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Randall E. Millikan has authored 87 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Surgery, 29 papers in Pulmonary and Respiratory Medicine and 26 papers in Oncology. Recurrent topics in Randall E. Millikan's work include Bladder and Urothelial Cancer Treatments (40 papers), Urinary and Genital Oncology Studies (27 papers) and Prostate Cancer Treatment and Research (15 papers). Randall E. Millikan is often cited by papers focused on Bladder and Urothelial Cancer Treatments (40 papers), Urinary and Genital Oncology Studies (27 papers) and Prostate Cancer Treatment and Research (15 papers). Randall E. Millikan collaborates with scholars based in United States, Spain and Japan. Randall E. Millikan's co-authors include Colin P. Dinney, Arlene O. Siefker‐Radtke, Christopher J. Logothetis, Peter F. Thall, Yu Shen, Lance C. Pagliaro, Ashish M. Kamat, Louis L. Pisters, H. Barton Grossman and Danai Daliani and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Journal of the American Statistical Association.

In The Last Decade

Randall E. Millikan

86 papers receiving 5.1k citations

Peers

Countries citing papers authored by Randall E. Millikan

Since Specialization

Citations

This map shows the geographic impact of Randall E. Millikan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Randall E. Millikan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Randall E. Millikan more than expected).

Fields of papers citing papers by Randall E. Millikan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Randall E. Millikan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Randall E. Millikan. The network helps show where Randall E. Millikan may publish in the future.

Co-authorship network of co-authors of Randall E. Millikan

This figure shows the co-authorship network connecting the top 25 collaborators of Randall E. Millikan. A scholar is included among the top collaborators of Randall E. Millikan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Randall E. Millikan. Randall E. Millikan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study 2016 ·BMC Cancer ·Farshid Dayyani, Amado J. Zurita, Graciela M. Nogueras‐González, Rebecca Slack, Randall E. Millikan, John C. Araujo, Gary E. Gallick, Christopher J. Logothetis, Paul G. Corn	11
2	A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer 2015 ·European Urology ·David J. McConkey, Woonyoung Choi, Yu Shen, (unknown), Sima P. Porten, Surena F. Matin, Ashish M. Kamat, Paul G. Corn, Randall E. Millikan, Colin P. Dinney, Bogdan Czerniak, Arlene O. Siefker‐Radtke	207
3	Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma 2014 ·Clinical Genitourinary Cancer ·Matthew T. Campbell, Randall E. Millikan, Emre Altinmakas, Lianchun Xiao, Sijin Wen, Arlene O. Siefker‐Radtke, Ana M. Aparicio, Paul G. Corn, Nizar M. Tannir	9
4	Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer 2013 ·Clinical Cancer Research ·Ana M. Aparicio, Andrea Harzstark, Paul G. Corn, Sijin Wen, John C. Araujo, Shi‐Ming Tu, Lance C. Pagliaro, Jeri Kim, Randall E. Millikan, Charles J. Ryan, Nizar M. Tannir, Amado J. Zurita, Paul Mathew, Wadih Arap, Patricia Troncoso, Peter F. Thall, Christopher J. Logothetis	311
5	Re: A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: Final results 2013 ·The Journal of Urology ·Arlene O. Siefker‐Radtke, Colin P. Dinney, Yali Shen, Dallas Williams, (unknown), H. Barton Grossman, Randall E. Millikan	0
6	Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer Improves Pathologic Downstaging and Long-term Outcomes: Results from a Retrospective Study at the MD Anderson Cancer Center 2012 ·European Urology ·(unknown), Yu Shen, Ashish M. Kamat, H. Barton Grossman, Jay B. Shah, Randall E. Millikan, Colin P. Dinney, Arlene O. Siefker‐Radtke	122
7	Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high‐risk upper tract transitional cell carcinoma 2010 ·Cancer ·Surena F. Matin, Vitaly Margulis, Ashish M. Kamat, Christopher G. Wood, H. Barton Grossman, Gordon Brown, Colin P. Dinney, Randall E. Millikan, Arlene O. Siefker‐Radtke	154
8	Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients With Metastatic Renal Cell Carcinoma 2009 ·Journal of Clinical Oncology ·Eric Jonasch, Christopher G. Wood, Surena F. Matin, Shi‐Ming Tu, Lance C. Pagliaro, Paul G. Corn, Ana M. Aparicio, Pheroze Tamboli, Randall E. Millikan, Xuemei Wang, John C. Araujo, Wadih Arap, Nizar M. Tannir	136
9	Bayesian and frequentist two‐stage treatment strategies based on sequential failure times subject to interval censoring 2007 ·Statistics in Medicine ·Peter F. Thall, (unknown), Christopher J. Logothetis, Randall E. Millikan, Nizar M. Tannir	50
10	Focus on bladder cancer 2004 ·Cancer Cell ·Colin P. Dinney, David J. McConkey, Randall E. Millikan, Xifeng Wu, Menashe Bar‐Eli, Liana Adam, Ashish M. Kamat, Arlene O. Siefker‐Radtke, Tomasz Tuziak, Anita L. Sabichi, H. Barton Grossman, William F. Benedict, Bogdan Czerniak	230
11	Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study 2003 ·Urologic Oncology Seminars and Original Investigations ·Jeri Kim, Randall E. Millikan, Terry L. Smith, Shi‐Ming Tu, Lance C. Pagliaro, Christopher J. Logothetis	4
12	Neoadjuvant chemotherapy for bladder cancer 2003 ·Urologic Oncology Seminars and Original Investigations ·Randall E. Millikan, Arlene O. Siefker‐Radtke, H. Barton Grossman	7
13	A Phase I/II study of strontium‐89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases 2003 ·Cancer ·Lance C. Pagliaro, Ebrahim S. Delpassand, Dallas Williams, Randall E. Millikan, Shi‐Ming Tu, Christopher J. Logothetis	22
14	Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. 2001 ·PubMed ·Joel W. Slaton, Takashi Karashima, Paul Perrotte, Keiji Inoue, Sun Jung Kim, Jonathan I. Izawa, Daniel Kedar, David J. McConkey, Randall E. Millikan, Paul Sweeney, Chiaki Yoshikawa, Taro Shuin, Colin P. Dinney	50
15	Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial 2001 ·The Lancet ·Shi‐Ming Tu, Randall E. Millikan, (unknown), Ebrahim S. Delpassand, Robert J. Amato, Lance C. Pagliaro, Danai Daliani, Christos N. Papandreou, Terry L. Smith, Jeri Kim, Donald A. Podoloff, Christopher J. Logothetis	277
16	Gemcitabine modulation of alkylator therapy 2001 ·Cancer ·Randall E. Millikan, William Plunkett, Terry Smith, Dallas Williams, C. Logothetis	13
17	Evaluating multiple treatment courses in clinical trials 2000 ·Statistics in Medicine ·Peter F. Thall, Randall E. Millikan, (unknown)	95
18	Phase II trial of 5-fluorouracil, interferon-? and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma 1997 ·Cancer ·Julie A. Ellerhorst, Avishay Sella, Robert J. Amato, Shi‐Ming Tu, Randall E. Millikan, Laury Finn, (unknown), Christopher J. Logothetis	37
19	Phase II trial of 5‐fluorouracil, interferon‐α and continuous infusion interleukin‐2 for patients with metastatic renal cell carcinoma 1997 ·Cancer ·Julie A. Ellerhorst, Avishay Sella, Robert J. Amato, Shi‐Ming Tu, Randall E. Millikan, Laury Finn, (unknown), Christopher J. Logothetis	2
20	Phase II study of doxorubicin, etoposide, and cisplatin for patients with small cell carcinoma of the prostate 1997 ·Danai Daliani, (unknown), Randall E. Millikan, (unknown), Julie A. Ellerhorst, R. J. Amato	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact